MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors

Nov 18, 2020

Article Link: https://www.mdanderson.org/newsroom/md-anderson-and-obsidian-therapeutics-announce-collaboration-to-advance-til-therapies.h00-159386679.html

Recent News

The Medicine Maker 2026 Power List

Celebrating 60 inspirational individuals – across small molecules, biopharma, and cell and gene therapy – who are helping to translate pharma’s...